During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

“It was encouraging to see that cabozantinib resulted in significant delays in disease progression in the CABINET trial—regardless of primary tumor site and grade. This FDA approval marks a ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older with pancreatic neuroendocrine tumors. The approval follows promising ...

The United States Food and Drug Administration has recently approved cabozantinib (Cabometyx) for patients with previously treated advanced neuroendocrine tumors. This is an oral tyrosine kinase ...

The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated ...

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib ...